Medpace Holdings, Inc. (MEDP): Total Liabilities
$1.52B
As of 2025-12-31
$1.62B
As of 2026-06-30
+16.2%
3-year compound annual growth
+21.0%
5-year compound annual growth
+10.3%
10-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $1.52B | +18.9% | 2026-02-10, Balance as of period end |
| 2024-12-31 | $1.28B | +16.2% | 2026-02-10, Balance as of period end |
| 2023-12-31 | $1.10B | +13.6% | 2025-02-11, Balance as of period end |
| 2022-12-31 | $966.11M | +36.6% | 2024-02-13, Balance as of period end |
| 2021-12-31 | $707.01M | +20.9% | 2023-02-14, Balance as of period end |
| 2020-12-31 | $584.90M | +40.3% | 2022-02-15, Balance as of period end |
| 2019-12-31 | $416.79M | +10.2% | 2021-02-16, Balance as of period end |
| 2018-12-31 | $378.23M | -15.4% | 2020-02-25, Balance as of period end |
| 2017-12-31 | $447.19M | +21.4% | 2019-02-26, Balance as of period end |
| 2016-12-31 | $368.39M | -35.4% | 2018-02-27, Balance as of period end |
| 2015-12-31 | $570.57M | n/a | 2017-02-28, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Medpace Holdings, Inc. (MEDP) | 2025-12-31 | $1.52B | +18.9% |
| Charles River Laboratories International, Inc. (CRL) | 2025-12-27 | $3.92B | -2.4% |
| Incyte Corp (INCY) | 2025-12-31 | $1.79B | -10.3% |
| Icon PLC (ICLR) | 2025-12-31 | $7.08B | -1.6% |
| Iqvia Holdings Inc. (IQV) | 2025-12-31 | $23.31B | +11.9% |
| NRC Health (NRC) | 2025-12-31 | $120.89M | +19.4% |
| MaxCyte, Inc. (MXCT) | 2025-12-31 | $31.02M | -6.6% |
| OmniAb, Inc. (OABI) | 2025-12-31 | $33.89M | -10.7% |
| Foxo Technologies Inc. (FOXO) | 2025-12-31 | $33.50M | -8.1% |
Compare MEDP, CRL, INCY, ICLR side by side · Screen every company in Services-Commercial Physical & Biological Research ↗